Clinical Research Directory

Inclusion Criteria: * Patients who underwent allogeneic hematopoietic stem cell transplantation (HSCT) between March 2019 and March 2024; * Donor had fasting blood glucose and/or HbA1c records * Eastern Cooperative Oncology Group (ECOG) physical fitness score of 0-2 * Survived at least 12 weeks after HSCT * Voluntarily signed the Informed Consent Form * Had appropriate organ function; * Laboratory results within 7 days prior to HSCT met the following criteria: 1. Aspartate aminotransferase (AST) ≤ 3-fold (upper limit of norma, ULN); 2. Alanine aminotransferase (ALT) ≤ 3x ULN; 3. Total serum bilirubin ≤ 1.5 times the upper limit of normal ULN unless the patient has documented Gilbert syndrome; patients with Gilbert-Meulengracht syndrome with bilirubin ≤ 3.0 times the upper limit of normal and direct bilirubin ≤ 1.5 times the upper limit of normal may be included; 4. Serum creatinine ≤ 1.5 times ULN or creatinine clearance ≥ 60 mL/min; 5. Coagulation function: International Normalized Ratio (INR) ≤1.5×ULN, Activated Partial Thromboplastin Time (APTT) ≤1.5×ULN; Exclusion Criteria: * Active autoimmune diseases such as SLE, rheumatoid arthritis, etc. * Active cardiovascular disease such as uncontrolled arrhythmias, uncontrolled hypertension, congestive heart failure, any Grade 3 or 4 heart disease as determined by the New York Heart Association (NYHA) Functional Class, or a history of myocardial infarction in the 6 months prior to screening; * Other serious medical conditions that may limit the patient's participation in this trial (e.g., progressive infection, uncontrolled diabetes); * HIV infection, or chronic infection with hepatitis B virus (HBsAg-positive) or hepatitis C virus (anti-HCV-positive) that cannot be controlled by medications; * Patients with other uncured tumors * Patients with neurological or psychiatric disorders * Patients who were unable to understand or comply with the research protocol or are unable to sign the Informed Consent Form